These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31387920)

  • 61. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV.
    Pakravan N; Hassan ZM
    Immunotherapy; 2018 Mar; 10(3):213-219. PubMed ID: 29370722
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
    Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
    [No Abstract]   [Full Text] [Related]  

  • 65. Harnessing the immune system for the treatment of breast cancer.
    Jiang X
    J Zhejiang Univ Sci B; 2014 Jan; 15(1):1-15. PubMed ID: 24390741
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cancer vaccines.
    Rousseau RF; Hirschmann-Jax C; Takahashi S; Brenner MK
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):741-73. PubMed ID: 11676282
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment duration with immune-based therapies in Cancer: an enigma.
    Bantia S; Choradia N
    J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy.
    Clift R; Souratha J; Garrovillo SA; Zimmerman S; Blouw B
    Cancer Res; 2019 Aug; 79(16):4149-4159. PubMed ID: 31248966
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 75. On combining antineoplastic drugs with tumor vaccines.
    Terando A; Mulé JJ
    Cancer Immunol Immunother; 2003 Nov; 52(11):680-5. PubMed ID: 12955481
    [No Abstract]   [Full Text] [Related]  

  • 76. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
    Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
    Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
    Zhao P; Zhu D; Zhang Z; Han B; Gao D; Wei X; Xie X; Li C; Sun W; Wang Q; Guo Q
    Immunol Lett; 2017 Jan; 181():36-44. PubMed ID: 27867030
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
    Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
    De Jaeghere EA; Denys HG; De Wever O
    Trends Cancer; 2019 Nov; 5(11):704-723. PubMed ID: 31735289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.